Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
136.26
-2.90 (-2.08%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
3
4
5
6
7
8
9
...
58
59
Next >
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
July 09, 2024
These high-potential stock picks each have 10X potential moving forward and are well worth understanding despite high prices in some cases.
Via
InvestorPlace
3 Stocks With the Potential to 10X Your Money
July 09, 2024
These three top high-growth potential stocks could offer substantial growth and give your portfolio a major boost.
Via
InvestorPlace
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
July 09, 2024
This pharma company is posting double-digit revenue growth.
Via
The Motley Fool
Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
July 09, 2024
Eli Lilly and Co has emerged victorious in the weight loss drug competition, in a recent study. The study found that patients on Lilly's Mounjaro lost more weight than those on Novo Nordisk's Ozempic.
Via
Benzinga
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic
July 08, 2024
Patients lost more more weight on Mounjaro than Ozempic.
Via
Investor's Business Daily
Will NVO Provide Any Buying Opportunity?
July 08, 2024
Novo Nordisk A/S, a healthcare company engages in the research, development, manufacture & marketing of the pharmaceutical products worldwide.
Via
Talk Markets
Looking for growth without the hefty price tag? Consider NYSE:NVO.
July 05, 2024
NYSE:NVO is showing decent growth, but is still valued reasonably.
Via
Chartmill
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
July 04, 2024
Via
Benzinga
3 Overlooked Giants-in-the-Making for Patient Investors
July 08, 2024
Consider buying into these overlooked growth stocks for long-term profits that will help to boost a portfolio and deliver riches.
Via
InvestorPlace
Novartis Stock Generating Improved Relative Strength
July 08, 2024
Top and bottom line growth moved higher in Novartis' most recent quarter. EPS rose 17% to $1.80. Revenue increased 10% to $12.1 billion.
Via
Investor's Business Daily
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
July 07, 2024
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs.
Via
Benzinga
Topics
ETFs
The 7 Best Under $10 Stocks to Buy in July 2024
July 06, 2024
We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now.
Via
InvestorPlace
Why Novo Nordisk Stock Is Slipping Today
July 02, 2024
President Biden and Sen. Bernie Sanders warned the drugmaker against "ripping off the American people."
Via
The Motley Fool
Copper, Gold Stocks Sparkle, Among 5 Leaders Near Buy Points
July 06, 2024
Southern Copper and Agnico Eagle surged above early entries.
Via
Investor's Business Daily
MarketBeat Week in Review – 7/1 - 7/5
July 06, 2024
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
July 05, 2024
A study finds that GLP-1 treatments, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, significantly reduce the risk of ten obesity-related cancers in type 2 diabetes patients, highlighting...
Via
Benzinga
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
July 05, 2024
UK regulators reprimand Novo Nordisk for failing to disclose nearly $10 million in fees and expenses. The PMCPA cites breaches in financial categorization and highlights similar issues with Novartis...
Via
Benzinga
Stock Market: S&P 500, Nasdaq Hit Highs As Tesla Soars, Rate-Cut Hopes Rise: Weekly Review
July 05, 2024
However, small caps fell. Cooling economic data raised rate-cut hopes.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Is It Too Late to Buy Novo Nordisk Stock?
July 05, 2024
It's possible for investors to be too late to the party with a stock -- can Novo Nordisk's party keep rolling?
Via
The Motley Fool
Did Vertex Pharmaceuticals Just Invent the Next Ozempic?
July 05, 2024
Vertex Pharmaceuticals likely has a breakthrough medicine on its hands.
Via
The Motley Fool
The 3 Best Healthcare Stocks to Buy in July 2024
July 04, 2024
Consistent breakthroughs, improved products and relatively consistent growth make these the best healthcare stocks to buy.
Via
InvestorPlace
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
July 03, 2024
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June’s sharply lower-than-expected services sector...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
July 03, 2024
New study suggests a potential link between Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, and NAION, a condition that can cause vision loss. Researchers urge further analysis and awareness for...
Via
Benzinga
Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
July 03, 2024
The study comes out of a Harvard teaching hospital based in Boston.
Via
Investor's Business Daily
The 7 Best Stocks to Buy in July 2024
July 03, 2024
Investors looking to for the best stocks to buy as we enter the year's second half and add some winners should consider these securities.
Via
InvestorPlace
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
July 03, 2024
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases
Via
MarketBeat
Exposures
Product Safety
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
July 02, 2024
The company is on deck to rival Biogen and Eisai's Leqembi.
Via
Investor's Business Daily
Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
July 02, 2024
American leaders push for lower drug prices, highlighting recent legislation and widespread support for affordable medications. The Inflation Reduction Act caps insulin costs and Medicare now...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Novo, Lilly Dive After Biden Slams Duo For 'Unconscionably High' Drug Prices
July 02, 2024
The duo make weight-loss and diabetes drugs that sell for more than $1,000 a month before insurance kicks in.
Via
Investor's Business Daily
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
July 02, 2024
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
...
58
59
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.